bioRxivCancer Biology
The beta-catenin-target Fascin-1, altering hepatocyte differentiation, is a new marker of immature cells in hepatoblastomas
C. Gest, S. Sena, V. Neaud, R. Loesch, N. Dugot-Senant, L. Paysan, L. Piquet, T. Robbe, N. Allain, D. Dembele, C. Guettier, P. Bioulac-Sage, B. Le Bail, C. Grosset, F. SALTEL, V. Lagree, S. Colnot, V. Moreau
Abstract
BACKGROUND & AIMS{beta}-catenin is a well-known effector of the Wnt pathway and a key player in cadherin-mediated cell adhesion. Oncogenic mutations of {beta}-catenin are highly frequent in pediatric liver primary tumors. Those mutations are mostly heterozygous allowing the co-expression of wild-type (WT) and mutated {beta}-catenins in tumor cells. We investigated the interplay between WT and mutated {beta}-catenins in liver tumor cells, and searched for new actors of the {beta}-catenin pathway. METHODSUsing an RNAi strategy in {beta}-catenin-mutated hepatoblastoma (HB) cells, we dissociated the structural and transcriptional activities of {beta}-catenin, carried mainly by, respectively, WT and mutated proteins. Their impact was characterized using transcriptomic and functional analyses. We studied mice that develop liver tumors upon activation of {beta}-catenin in hepatocytes (APCKO and {beta}-catenin{Delta}exon3 mice). We made use of transcriptomic data from mouse and human HB specimens and analyzed samples by immunohistochemistry. RESULTSWe highlighted an antagonist role of WT and mutated {beta}-catenins on hepatocyte differentiation as attested by alteration of hepatocyte markers expression and bile canaliculi formation. We characterized Fascin-1 as a target of {beta}-catenin involved in hepatocyte differentiation. Using mouse models that allow the formation of two phenotypically distinct tumors (differentiated or undifferentiated), we found that Fascin-1 expression is higher in undifferentiated tumors. Finally, we found that Fascin-1 is a specific marker of the embryonal component in human HBs. CONCLUSIONSIn mice and human, Fascin-1 expression is linked to loss of differentiation and polarity of hepatocytes. Thus, we highlighted Fascin-1 as a new player in the modulation of hepatocyte differentiation associated to {beta}-catenin pathway alteration in the liver. Data Transparency Statementstudy materials will be made available to other researchers upon request.
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Deleting in vivo β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumors
- Differential Wnt/β-Catenin Signaling via TCF7L2/LEF1 Binding Specificity Shapes Cellular and Tumor Phenotypes
Thomas A. Kluiver, Anna Nordin, … Weng Chuan Peng·bioRxiv·Nov 4, 2025
- Cholangiocytic differentiation drives cell proliferation in hepatoblastoma through Wnt-dependent FGF19 signaling
- Canonical Wnt signalling is activated during BEC-to-hepatocyte conversion in vivo and modulates liver epithelial cell plasticity in hepatic organoids
E. Valle-Encinas, N. Aleksieva, … T. C. Dale·bioRxiv·Nov 9, 2020
- Hepatocellular carcinoma-associated AXIN1 mutations drive low levels of Wnt/β-catenin pathway activity that allow for niche-independent growth and YAP/TAZ signaling
Anton Jan Venhuizen, Yvanka van Os, … Madelon M. Maurice·iSciencePeer-reviewed·Dec 20, 2025
- New three-dimensional preclinical models to understand and treat liver cancers activated for the β-catenin pathway
Vanessa Bou Malham, Fanny Léandre, … Christèle Desbois‐Mouthon·bioRxiv·Apr 3, 2026